{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T12:59:20Z","timestamp":1780750760962,"version":"3.54.1"},"publisher-location":"New York, NY","reference-count":51,"publisher":"Springer US","isbn-type":[{"value":"9781071647295","type":"print"},{"value":"9781071647301","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-1-0716-4730-1_22","type":"book-chapter","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T12:59:23Z","timestamp":1753707563000},"page":"329-343","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["In Vivo Evaluation of Multiple Exon Skipping with Peptide-PMOs in Cardiac and Skeletal Muscles in Dystrophic Dogs"],"prefix":"10.1007","author":[{"given":"Rika","family":"Maruyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitsugu","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin\u2019ichi","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"issue":"6","key":"22_CR1","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","volume":"51","author":"EP Hoffman","year":"1987","unstructured":"Hoffman EP, Brown RH Jr, Kunkel LM (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51(6):919\u2013928","journal-title":"Cell"},{"issue":"363","key":"22_CR2","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1136\/bmj.2.363.541","volume":"2","author":"Duchenne","year":"1867","unstructured":"Duchenne (1867) The pathology of paralysis with muscular degeneration (Paralysie Myosclerotique), or paralysis with apparent hypertrophy. Br Med J 2(363):541\u2013542","journal-title":"Br Med J"},{"issue":"3","key":"22_CR3","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ncl.2014.05.002","volume":"32","author":"KM Flanigan","year":"2014","unstructured":"Flanigan KM (2014) Duchenne and Becker muscular dystrophies. Neurol Clin 32(3):671\u2013688, viii. https:\/\/doi.org\/10.1016\/j.ncl.2014.05.002","journal-title":"Neurol Clin"},{"issue":"4","key":"22_CR4","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/jhg.2016.152","volume":"62","author":"A Nakamura","year":"2017","unstructured":"Nakamura A, Shiba N, Miyazaki D et al (2017) Comparison of the phenotypes of patients harboring in-frame deletions starting at exon 45 in the Duchenne muscular dystrophy gene indicates potential for the development of exon skipping therapy. J Hum Genet 62(4):459\u2013463. https:\/\/doi.org\/10.1038\/jhg.2016.152","journal-title":"J Hum Genet"},{"issue":"7","key":"22_CR5","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/jhg.2016.28","volume":"61","author":"A Nakamura","year":"2016","unstructured":"Nakamura A, Fueki N, Shiba N et al (2016) Deletion of exons 3-9 encompassing a mutational hot spot in the DMD gene presents an asymptomatic phenotype, indicating a target region for multiexon skipping therapy. J Hum Genet 61(7):663\u2013667. https:\/\/doi.org\/10.1038\/jhg.2016.28","journal-title":"J Hum Genet"},{"issue":"8","key":"22_CR6","first-page":"1314","volume":"7","author":"X Yu","year":"2015","unstructured":"Yu X, Bao B, Echigoya Y et al (2015) Dystrophin-deficient large animal models: translational research and exon skipping. Am J Transl Res 7(8):1314\u20131331","journal-title":"Am J Transl Res"},{"key":"22_CR7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/978-4-431-55678-7_6","volume-title":"Translational research in muscular dystrophy","author":"J Lee","year":"2016","unstructured":"Lee J, Yokota T (2016) Translational research in nucleic acid therapies for muscular dystrophies. In: Takeda S, Miyagoe-Suzuki Y, Mori-Yoshimura M (eds) Translational research in muscular dystrophy. Springer, Tokyo, Japan, pp 87\u2013102. https:\/\/doi.org\/10.1007\/978-4-431-55678-7_6"},{"issue":"16","key":"22_CR8","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.1073\/pnas.1613203114","volume":"114","author":"Y Echigoya","year":"2017","unstructured":"Echigoya Y, Nakamura A, Nagata T et al (2017) Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy. Proc Natl Acad Sci USA 114(16):4213\u20134218. https:\/\/doi.org\/10.1073\/pnas.1613203114","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"22_CR9","doi-asserted-by":"publisher","first-page":"8174","DOI":"10.1093\/nar\/gku512","volume":"42","author":"T Shimo","year":"2014","unstructured":"Shimo T, Tachibana K, Saito K et al (2014) Design and evaluation of locked nucleic acid-based splice-switching oligonucleotides in vitro. Nucleic Acids Res 42(12):8174\u20138187. https:\/\/doi.org\/10.1093\/nar\/gku512","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"22_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3233\/JND-150113","volume":"3","author":"M Rodrigues","year":"2016","unstructured":"Rodrigues M, Echigoya Y, Fukada S et al (2016) Current translational research and murine models for Duchenne muscular dystrophy. J Neuromuscular Diseases 3(1):29\u201348","journal-title":"J Neuromuscular Diseases"},{"issue":"9","key":"22_CR11","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1517\/14712598.2012.693469","volume":"12","author":"T Yokota","year":"2012","unstructured":"Yokota T, Duddy W, Echigoya Y et al (2012) Exon skipping for nonsense mutations in Duchenne muscular dystrophy: too many mutations, too few patients? Expert Opin Biol Ther 12(9):1141\u20131152. https:\/\/doi.org\/10.1517\/14712598.2012.693469","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"22_CR12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3233\/JND-170233","volume":"4","author":"N Wein","year":"2017","unstructured":"Wein N, Vulin A, Findlay AR et al (2017) Efficient skipping of single exon duplications in DMD patient-derived cell lines using an antisense oligonucleotide approach. J Neuromuscul Dis 4(3):199\u2013207. https:\/\/doi.org\/10.3233\/JND-170233","journal-title":"J Neuromuscul Dis"},{"key":"22_CR13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/978-1-4939-6817-6_17","volume":"1565","author":"R Maruyama","year":"2017","unstructured":"Maruyama R, Echigoya Y, Caluseriu O et al (2017) Systemic delivery of Morpholinos to skip multiple exons in a dog model of Duchenne muscular dystrophy. Methods Mol Biol 1565:201\u2013213. https:\/\/doi.org\/10.1007\/978-1-4939-6817-6_17","journal-title":"Methods Mol Biol"},{"issue":"5","key":"22_CR14","doi-asserted-by":"publisher","first-page":"431","DOI":"10.2174\/1389201043376706","volume":"5","author":"V Arora","year":"2004","unstructured":"Arora V, Devi GR, Iversen PL (2004) Neutrally charged phosphorodiamidate morpholino antisense oligomers: uptake, efficacy and pharmacokinetics. Curr Pharm Biotechnol 5(5):431\u2013439","journal-title":"Curr Pharm Biotechnol"},{"key":"22_CR15","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/DDDT.S97635","volume":"11","author":"KR Lim","year":"2017","unstructured":"Lim KR, Maruyama R, Yokota T (2017) Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Devel Ther 11:533\u2013545. https:\/\/doi.org\/10.2147\/DDDT.S97635","journal-title":"Drug Des Devel Ther"},{"issue":"5","key":"22_CR16","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/ana.23982","volume":"74","author":"JR Mendell","year":"2013","unstructured":"Mendell JR, Rodino-Klapac LR, Sahenk Z et al (2013) Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol 74(5):637\u2013647. https:\/\/doi.org\/10.1002\/ana.23982","journal-title":"Ann Neurol"},{"key":"22_CR17","doi-asserted-by":"publisher","unstructured":"Nguyen Q, Yokota T (2017) Immortalized muscle cell model to test the exon skipping efficacy for Duchenne muscular dystrophy. J Personalized Med 7(4). https:\/\/doi.org\/10.3390\/jpm7040013","DOI":"10.3390\/jpm7040013"},{"issue":"1","key":"22_CR18","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1073\/pnas.0406700102","volume":"102","author":"QL Lu","year":"2005","unstructured":"Lu QL, Rabinowitz A, Chen YC et al (2005) Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci USA 102(1):198\u2013203. https:\/\/doi.org\/10.1073\/pnas.0406700102","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"22_CR19","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/ana.21627","volume":"65","author":"T Yokota","year":"2009","unstructured":"Yokota T, Lu QL, Partridge T et al (2009) Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol 65(6):667\u2013676. https:\/\/doi.org\/10.1002\/ana.21627","journal-title":"Ann Neurol"},{"issue":"13","key":"22_CR20","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.4155\/fmc.15.116","volume":"7","author":"A Guncay","year":"2015","unstructured":"Guncay A, Yokota T (2015) Antisense oligonucleotide drugs for Duchenne muscular dystrophy: how far have we come and what does the future hold? Future Med Chem 7(13):1631\u20131635. https:\/\/doi.org\/10.4155\/fmc.15.116","journal-title":"Future Med Chem"},{"issue":"6","key":"22_CR21","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1517\/14712598.2014.896335","volume":"14","author":"A Touznik","year":"2014","unstructured":"Touznik A, Lee JJ, Yokota T (2014) New developments in exon skipping and splice modulation therapies for neuromuscular diseases. Expert Opin Biol Ther 14(6):809\u2013819. https:\/\/doi.org\/10.1517\/14712598.2014.896335","journal-title":"Expert Opin Biol Ther"},{"issue":"11","key":"22_CR22","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1038\/mt.2010.186","volume":"18","author":"Y Aoki","year":"2010","unstructured":"Aoki Y, Nakamura A, Yokota T et al (2010) In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse. Molecular Therapy: J American Soc Gene Therapy 18(11):1995\u20132005. https:\/\/doi.org\/10.1038\/mt.2010.186","journal-title":"Molecular Therapy: J American Soc Gene Therapy"},{"key":"22_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2014.8","volume":"3","author":"KL Greer","year":"2014","unstructured":"Greer KL, Lochmuller H, Flanigan K et al (2014) Targeted exon skipping to correct exon duplications in the dystrophin gene. Mol Ther Nucleic Acids 3:e155. https:\/\/doi.org\/10.1038\/mtna.2014.8","journal-title":"Mol Ther Nucleic Acids"},{"issue":"16","key":"22_CR24","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.2174\/1381612811319160010","volume":"19","author":"HM Moulton","year":"2013","unstructured":"Moulton HM (2013) In vivo delivery of morpholino oligos by cell-penetrating peptides. Curr Pharm Des 19(16):2963\u20132969","journal-title":"Curr Pharm Des"},{"key":"22_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2012.30","volume":"1","author":"C Betts","year":"2012","unstructured":"Betts C, Saleh AF, Arzumanov AA et al (2012) Pip6-PMO, a new generation of peptide-oligonucleotide conjugates with improved cardiac exon skipping activity for DMD treatment. Mol Ther Nucleic Acids 1:e38. https:\/\/doi.org\/10.1038\/mtna.2012.30","journal-title":"Mol Ther Nucleic Acids"},{"issue":"7","key":"22_CR26","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/mt.2011.79","volume":"19","author":"H Yin","year":"2011","unstructured":"Yin H, Saleh AF, Betts C et al (2011) Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. Mol Ther J American Soc Gene Ther 19(7):1295\u20131303. https:\/\/doi.org\/10.1038\/mt.2011.79","journal-title":"Mol Ther J American Soc Gene Ther"},{"issue":"2","key":"22_CR27","first-page":"93","volume":"52","author":"Y Shimatsu","year":"2003","unstructured":"Shimatsu Y, Katagiri K, Furuta T et al (2003) Canine X-linked muscular dystrophy in Japan (CXMDJ). Experimental Animals Japanese Assoc Laboratory Animal Sci 52(2):93\u201397","journal-title":"Experimental Animals Japanese Assoc Laboratory Animal Sci"},{"issue":"2","key":"22_CR28","first-page":"145","volume":"24","author":"Y Shimatsu","year":"2005","unstructured":"Shimatsu Y, Yoshimura M, Yuasa K et al (2005) Major clinical and histopathological characteristics of canine X-linked muscular dystrophy in Japan, CXMDJ. Acta Myologica: Myopathies Cardiomyopathies: Official J Mediterranean Soc Myology \/ Edited Gaetano Conte Academy Study Striated Muscle Diseases 24(2):145\u2013154","journal-title":"Acta Myologica: Myopathies Cardiomyopathies: Official J Mediterranean Soc Myology \/ Edited Gaetano Conte Academy Study Striated Muscle Diseases"},{"issue":"19","key":"22_CR29","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1161\/CIRCULATIONAHA.107.739326","volume":"117","author":"N Urasawa","year":"2008","unstructured":"Urasawa N, Wada MR, Machida N et al (2008) Selective vacuolar degeneration in dystrophin-deficient canine Purkinje fibers despite preservation of dystrophin-associated proteins with overexpression of Dp71. Circulation 117(19):2437\u20132448","journal-title":"Circulation"},{"key":"22_CR30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1471-2261-6-47","volume":"6","author":"N Yugeta","year":"2006","unstructured":"Yugeta N, Urasawa N, Fujii Y et al (2006) Cardiac involvement in beagle-based canine X-linked muscular dystrophy in Japan (CXMDJ): electrocardiographic, echocardiographic, and morphologic studies. BMC Cardiovasc Disord 6:47. https:\/\/doi.org\/10.1186\/1471-2261-6-47","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"22_CR31","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/0888-7543(92)90210-J","volume":"13","author":"NJ Sharp","year":"1992","unstructured":"Sharp NJ, Kornegay JN, Van Camp SD et al (1992) An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy. Genomics 13(1):115\u2013121","journal-title":"Genomics"},{"key":"22_CR32","doi-asserted-by":"publisher","unstructured":"Miskew Nichols B, Aoki Y, Kuraoka M et al (2016) Multi-exon skipping using cocktail antisense oligonucleotides in the canine X-linked muscular dystrophy. J Visualized Exper: JoVE 111. https:\/\/doi.org\/10.3791\/53776","DOI":"10.3791\/53776"},{"issue":"1","key":"22_CR33","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1089\/nat.2013.0451","volume":"24","author":"Y Echigoya","year":"2014","unstructured":"Echigoya Y, Yokota T (2014) Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides. Nucleic Acid Ther 24(1):57\u201368. https:\/\/doi.org\/10.1089\/nat.2013.0451","journal-title":"Nucleic Acid Ther"},{"issue":"3","key":"22_CR34","first-page":"179","volume":"26","author":"T Yokota","year":"2007","unstructured":"Yokota T, Duddy W, Partridge T (2007) Optimizing exon skipping therapies for DMD. Acta Myologica: Myopathies Cardiomyopathies: Official J Mediterranean Soc Myology \/ Edited Gaetano Conte Academy for the Study of Striated Muscle Diseases 26(3):179\u2013184","journal-title":"Acta Myologica: Myopathies Cardiomyopathies: Official J Mediterranean Soc Myology \/ Edited Gaetano Conte Academy for the Study of Striated Muscle Diseases"},{"issue":"1","key":"22_CR35","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1001\/archneurol.2008.540","volume":"66","author":"T Yokota","year":"2009","unstructured":"Yokota T, Takeda S, Lu QL et al (2009) A renaissance for antisense oligonucleotide drugs in neurology: exon skipping breaks new ground. Arch Neurol 66(1):32\u201338. https:\/\/doi.org\/10.1001\/archneurol.2008.540","journal-title":"Arch Neurol"},{"issue":"1","key":"22_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biomedicines6010001","volume":"6","author":"T Aslesh","year":"2018","unstructured":"Aslesh T, Maruyama R, Yokota T (2018) Skipping multiple exons to treat DMD\u2014promises and challenges. Biomedicines 6(1):1","journal-title":"Biomedicines"},{"issue":"7","key":"22_CR37","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jocn.2006.12.012","volume":"15","author":"A Nakamura","year":"2008","unstructured":"Nakamura A, Yoshida K, Fukushima K et al (2008) Follow-up of three patients with a large in-frame deletion of exons 45-55 in the Duchenne muscular dystrophy (DMD) gene. J Clin Neurosci 15(7):757\u2013763","journal-title":"J Clin Neurosci"},{"key":"22_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2014.76","volume":"4","author":"Y Echigoya","year":"2015","unstructured":"Echigoya Y, Aoki Y, Miskew B et al (2015) Long-term efficacy of systemic multiexon skipping targeting dystrophin exons 45-55 with a cocktail of vivo-morpholinos in mdx52 mice. Mol Ther Nucleic Acids 4:e225. https:\/\/doi.org\/10.1038\/mtna.2014.76","journal-title":"Mol Ther Nucleic Acids"},{"issue":"34","key":"22_CR39","doi-asserted-by":"publisher","first-page":"13763","DOI":"10.1073\/pnas.1204638109","volume":"109","author":"Y Aoki","year":"2012","unstructured":"Aoki Y, Yokota T, Nagata T et al (2012) Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. Proc Natl Acad Sci USA 109(34):13763\u201313768. https:\/\/doi.org\/10.1073\/pnas.1204638109","journal-title":"Proc Natl Acad Sci USA"},{"key":"22_CR40","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/402369","volume":"2013","author":"Y Aoki","year":"2013","unstructured":"Aoki Y, Yokota T, Wood MJ (2013) Development of multiexon skipping antisense oligonucleotide therapy for Duchenne muscular dystrophy. Biomed Res Int 2013:402369. https:\/\/doi.org\/10.1155\/2013\/402369","journal-title":"Biomed Res Int"},{"key":"22_CR41","first-page":"18","volume-title":"Molecular therapy","author":"R Maruyama","year":"2017","unstructured":"Maruyama R, Echigoya Y, Nakamura A et al (2017) Systemic injections of peptide-conjugated morpholinos improve cardiac symptoms of a dog model of duchenne muscular dystrophy. In: Molecular therapy, vol 5. Cell Press, Cambridge, MA, p 18"},{"issue":"13","key":"22_CR42","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.1093\/nar\/gkg616","volume":"31","author":"L Cartegni","year":"2003","unstructured":"Cartegni L, Wang J, Zhu Z et al (2003) ESEfinder: a web resource to identify exonic splicing enhancers. Nucleic Acids Res 31(13):3568\u20133571","journal-title":"Nucleic Acids Res"},{"issue":"Web Server","key":"22_CR43","doi-asserted-by":"publisher","first-page":"W187","DOI":"10.1093\/nar\/gkh393","volume":"32","author":"WG Fairbrother","year":"2004","unstructured":"Fairbrother WG, Yeo GW, Yeh R et al (2004) RESCUE-ESE identifies candidate exonic splicing enhancers in vertebrate exons. Nucleic Acids Research 32(Web Server):W187\u2013W190. https:\/\/doi.org\/10.1093\/nar\/gkh393","journal-title":"Nucleic Acids Research"},{"key":"22_CR44","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/978-1-61779-767-5_26","volume":"867","author":"HM Moulton","year":"2012","unstructured":"Moulton HM (2012) Cell-penetrating peptides enhance systemic delivery of antisense morpholino oligomers. Methods Mol Biol 867:407\u2013414. https:\/\/doi.org\/10.1007\/978-1-61779-767-5_26","journal-title":"Methods Mol Biol"},{"key":"22_CR45","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/978-1-61737-982-6_20","volume":"709","author":"T Yokota","year":"2011","unstructured":"Yokota T, Hoffman E, Takeda S (2011) Antisense oligo-mediated multiple exon skipping in a dog model of duchenne muscular dystrophy. Methods Mol Biol 709:299\u2013312. https:\/\/doi.org\/10.1007\/978-1-61737-982-6_20","journal-title":"Methods Mol Biol"},{"issue":"1","key":"22_CR46","first-page":"23","volume":"22","author":"LP Tilley","year":"1981","unstructured":"Tilley LP (1981) Basic canine and feline electrocardiography. Can Vet J 22(1):23\u201324","journal-title":"Can Vet J"},{"key":"22_CR47","doi-asserted-by":"publisher","unstructured":"Echigoya Y, Lim KRQ, Trieu N et al (2017) Quantitative antisense screening and optimization for exon 51 skipping in Duchenne muscular dystrophy. Molecular Therapy: J American Soc Gene Therapy. https:\/\/doi.org\/10.1016\/j.ymthe.2017.07.014","DOI":"10.1016\/j.ymthe.2017.07.014"},{"issue":"3","key":"22_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120058","volume":"10","author":"Y Echigoya","year":"2015","unstructured":"Echigoya Y, Mouly V, Garcia L et al (2015) In silico screening based on predictive algorithms as a design tool for exon skipping oligonucleotides in Duchenne muscular dystrophy. PLoS One 10(3):e0120058. https:\/\/doi.org\/10.1371\/journal.pone.0120058","journal-title":"PLoS One"},{"issue":"5","key":"22_CR49","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1089\/nat.2012.0368","volume":"22","author":"T Yokota","year":"2012","unstructured":"Yokota T, Nakamura A, Nagata T et al (2012) Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs. Nucleic Acid Therapeutics 22(5):306\u2013315. https:\/\/doi.org\/10.1089\/nat.2012.0368","journal-title":"Nucleic Acid Therapeutics"},{"key":"22_CR50","unstructured":"Shimo T, Mraruyama R, Yokota T (In Press) Designing effective antisense oligonucleotides for exon skipping. In: Methods in Molecular Biology"},{"issue":"24","key":"22_CR51","doi-asserted-by":"publisher","first-page":"4914","DOI":"10.1093\/hmg\/ddt341","volume":"22","author":"Y Aoki","year":"2013","unstructured":"Aoki Y, Nagata T, Yokota T et al (2013) Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-alpha2 chain-null congenital muscular dystrophy mice. Hum Mol Genet 22(24):4914\u20134928. https:\/\/doi.org\/10.1093\/hmg\/ddt341","journal-title":"Hum Mol Genet"}],"container-title":["Methods in Molecular Biology","Exon Skipping and Inclusion Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-4730-1_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T12:06:07Z","timestamp":1780747567000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-4730-1_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9781071647295","9781071647301"],"references-count":51,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-4730-1_22","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"29 July 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}